Epix/Schering gain European approval for Vasovist MRA (magnetic resonance angiography) contrast agent
This article was originally published in Clinica
Epix Pharmaceuticals has made its market debut after gaining European clearance for Vasovist - the first imaging agent specifically designed for magnetic resonance angiography (MRA). Epix' worldwide marketing partner, Schering, says it expects to commercialise the product in all 25 member states of the EU by early 2006.
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.